Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.

被引：2
作者：
Taylor, Matthew H.
Vogelzang, Nicholas J.
Cohn, Allen Lee
Stepan, Daniel E.
Shumaker, Robert Charles
Dutcus, Corina E.
Guo, Matthew
Schmidt, Emmett V.
Rasco, Drew W.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[3] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA
[4] Eisai Inc, Woodcliff Lake, NJ USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors (vol 17, pg 861, 2020)
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2702 - 2702
  • [22] Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
    Van Le, Linda
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2022, 77 (05) : 275 - 276
  • [23] Lenvatinib plus Pembrolizumab in advanced Endometrial Carcinoma
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (05) : 464 - 464
  • [24] Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
    Makker, V
    Colombo, N.
    Casado Herraez, A.
    Santin, A. D.
    Colomba, E.
    Miller, D. S.
    Fujiwara, K.
    Pignata, S.
    Baron-Hay, S.
    Ray-Coquard, I
    Shapira-Frommer, R.
    Ushijima, K.
    Sakata, J.
    Yonemori, K.
    Kim, Y. M.
    Guerra, E. M.
    Sanli, U. A.
    McCormack, M. M.
    Smith, A. D.
    Keefe, S.
    Bird, S.
    Dutta, L.
    Orlowski, R. J.
    Lorusso, D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) : 437 - 448
  • [25] A PHASE IB TRIAL OF ZIV-AFLIBERCEPT PLUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Tyan, Kevin
    Rahma, Osama
    Giobbie-Hurder, Anita
    Brohl, Andrew
    Bedard, Philippe
    Renouf, Daniel
    Sharon, Elad
    Streicher, Howard
    Hathaway, Emma
    Cunningham, Rachel
    Manos, Michael
    Severgnini, Mariano
    Rodig, Scott
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A402 - A404
  • [26] A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
    Chen, Tom Wei-Wu
    Hsu, Chia-Lang
    Hong, Ruey-Long
    Lee, Jen-Chieh
    Chang, Koping
    Yu, Chih-Wei
    Chen, San-Chi
    Guo, Jhe-Cyuan
    Chen, Mei-Lu
    Hsu, Meng-Chi
    Kung, Ting-Fang
    Cheng, Ann-Lii
    Yen, Chueh-Chuan
    CLINICAL CANCER RESEARCH, 2022, 28 (23) : 5058 - 5065
  • [27] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
    Zhu, Andrew X.
    Finn, Richard S.
    Ikeda, Masafumi
    Sung, Max W.
    Baron, Ari David
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.
    Patel, Sapna Pradyuman
    Othus, Megan
    Moon, James
    Tetzlaff, Michael T.
    Buchbinder, Elizabeth Iannotti
    Sondak, Vernon K.
    Lowe, Michael C.
    Campos, Danae
    Sharon, Elad
    Korde, Larissa A.
    Carson, William Edgar
    Ribas, Antoni
    Grossmann, Kenneth F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A phase I trial of panobinostat with ipilimumab in advanced melanoma.
    Khushalani, Nikhil I.
    Markowitz, Joseph
    Eroglu, Zeynep
    Giuroiu, Iulia
    Ladanova, Viktoriya
    Reiersen, Pamela
    Rich, Jeani
    Thapa, Ram
    Schell, Michael J.
    Sotomayor, Eduardo M.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] An open-label phase 1 trial of lenvatinib plus pembrolizumab in patients with advanced selected solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Iizumi, Sakura
    Ikezawa, Hiroki
    Namiki, Masayuki
    Kubota, Tomoki
    Miura, Takuma
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2018, 29
12345